Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
8
×
fda
8
×
life sciences
national blog main
biotech
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san diego blog main
san francisco blog main
san francisco top stories
indiana blog main
san diego top stories
boston
deals
europe top stories
indiana top stories
national
raleigh-durham blog main
seattle blog main
alnylam pharmaceuticals
boston university
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
europe blog main
gene therapy
investing
novartis
raleigh-durham top stories
regeneron pharmaceuticals
rna interference
roche
seattle top stories
texas blog main
texas top stories
What
patients
8
×
fda
drug
medicine
daily
diabetes
friday
help
million
startup
therapy
time
add
ago
alnylam
analytics
approval
approve
approved
aren’t
atrophy
awaits
beta
bid
bio
biofourmis
biological
bionics
blood
boehringer
called
cancer
carbidopa
closed
combination
control
crossed
data
decades
decision
Language
unset
Current search:
fda
×
patients
×
" clinical trials "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision